Overview

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Status:
Recruiting
Trial end date:
2023-02-14
Target enrollment:
Participant gender:
Summary
This is a double-blinded, two-arm, phase II study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis. The study includes a screening period, a treatment period and a follow-up period. At most, the study duration is 19 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals